Virginia is currently home to 1868 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
NCT03127267
Recruiting
The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS).
Gender:
All
Ages:
Between 18 years and 81 years
Trial Updated:
04/14/2023
Locations: University of Virginia Health System, Charlottesville, Virginia
Conditions: Amyotrophic Lateral Sclerosis
Register for Updates
Screening for High Frequency Malignant Disease
NCT05117840
Recruiting
The SHIELD (Screening for High Frequency Malignant Disease) study is a prospective, observational, multi-site basket design trial without randomization. The primary objective of the study is to evaluate the sensitivity and specificity of a blood-based GuardantLUNAR-2 test to detect high frequency cancer in screen-relevant populations.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
04/10/2023
Locations: Tidewater Physicians Multispecialty Group, P.C., Williamsburg, Virginia
Conditions: Lung Cancer
Register for Updates
ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma
NCT04480502
Recruiting
This is a multicenter open-label, randomized, non-comparative, parallel cohort pivotal study of treatment with envafolimab (cohort A and C) or envafolimab combined with ipilimumab (cohort B and D) in patients with locally advanced, unresectable or metastatic undifferentiated pleomorphic sarcoma (UPS)/myxofibrosarcoma (MFS) who have progressed on one or two lines of chemotherapy.
Gender:
All
Ages:
12 years and above
Trial Updated:
04/10/2023
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Undifferentiated Pleomorphic Sarcoma, Myxofibrosarcoma
Register for Updates
Exercise Dose and Metformin for Vascular Health in Adults With Metabolic Syndrome
NCT03355469
Recruiting
Health organizations recommend exercise in an intensity based manner to promote cardiovascular adaptation and prevent disease. Metformin is a common anti-diabetes medication that reduces future type 2 diabetes and cardiovascular disease (CVD) risk. However, the optimal dose of exercise to be combined with metformin for vascular health remains unknown. The purpose of this study is to evaluate whether combining high or low intensity exercise with metformin has the potential to outperform either ex... Read More
Gender:
All
Ages:
Between 40 years and 70 years
Trial Updated:
04/10/2023
Locations: University of Virginia, Charlottesville, Virginia
Conditions: Metabolic Syndrome
Register for Updates
Study to Evaluate the Reliability, Validity and Safety of Subjective Mobile Refraction
NCT05049070
Recruiting
This study evaluates the reliability, validity and safety of a self administered, subjective refraction test via a mobile medical app (GoEyes) as compared to standard of care subjective manifest refraction performed by a health care provider, in subjects who have no known ocular disease or condition other than refractive error.
Gender:
All
Ages:
Between 18 years and 39 years
Trial Updated:
04/04/2023
Locations: Wagner Macula & Retina, Norfolk, Virginia
Conditions: Refractive Errors
Register for Updates
The Hancock Jaffe Surgical Antireflux Venous Valve Endoprosthesis Study
NCT04943172
Recruiting
A prospective, non blinded, single arm, multicenter study designed to assess the safety and effectiveness of the bioprosthetic, VenoValve, which is surgically implanted into the deep venous system for treatment of patients with deep venous valvular insufficiency ( C4b-C6 patients).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/04/2023
Locations: Sentara, Norfolk, Virginia
Conditions: Deep Venous Insufficiency (Diagnosis)
Register for Updates
A Phase I/II Dose Escalation and Expansion Study of BST-236 Plus Venetoclax in Patients With Unfit Newly Diagnosed AML
NCT05503355
Recruiting
An open label multi centre study to assess the safety and efficacy of BST-236 in combination with venetoclax in adult patients unfit for standard therapy with newly diagnosed Acute Myeloid Leukemia (AML) Part 1 of the study will define the maximal tolerate dose of the combination treatment, while part 2 will expend the chosen dose, to assesses efficacy and safety of this combination. All patients will receive 2 induction courses with both BST-236 and venetoclax, responding patients will then be... Read More
Gender:
All
Ages:
Between 18 years and 90 years
Trial Updated:
04/02/2023
Locations: University of Virginia Cancer Center, Charlottesville, Virginia
Conditions: AML, Adult
Register for Updates
Study BT7480-100 in Patients With Advanced Malignancies Associated With Nectin-4 Expression
NCT05163041
Recruiting
This clinical study is evaluating a drug called BT7480 alone and in combination with nivolumab in participants with advanced solid tumors associated with Nectin-4 expression. The main goals of the study are to: Find the recommended dose of BT7480 that can be given safely to participants alone and in combination with nivolumab Learn about the side effects and effectiveness of BT7480 alone and in combination with nivolumab Learn about the effect BT7480 has on the body and how BT7480 is cleared b... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/30/2023
Locations: Virginia Cancer Specialists, Fairfax, Virginia
Conditions: Advanced Solid Tumor
Register for Updates
IMM2902, a HER2/SIRPα Bispecific mAb-Trap Antibody-receptor Fusion Protein, in Patients With HER2-expressing Advanced Solid Tumors
NCT05076591
Recruiting
This trial is a first-in-human, open label, multi-center, dose escalation phase 1a study followed by a disease-specific dose expansion phase 1b study to evaluate the safety, efficacy, and pharmacokinetics (PK) of IMM2902, a HER2/SIRPα bispecific mAb-Trap antibody-receptor fusion protein, in patients with HER2-expressing advanced solid tumor.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2023
Locations: NEXT Virginia, LLC, Fairfax, Virginia
Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Advanced Gastric Cancer
Register for Updates
Immuno-bridging and Broadening Study of a Whole, Inactivated COVID-19 Vaccine BBV152 in Healthy Adults
NCT05258669
Recruiting
A randomized, observer-blind, placebo-controlled immuno-bridging, and broadening study to demonstrate the equivalence of the immune response between participants enrolled in Phase 3 efficacy trial in India and demographically diverse healthy adult participants in the US which matched in age and vaccine formulation setting to whom those efficacy results are extrapolated; and to assess the broadening of the BBV152 in participants who previously received two shots of messenger ribonucleic acid (mRN... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/24/2023
Locations: Meridian Research 3235 Academy Ave, Portsmouth, Virginia
Conditions: COVID-19
Register for Updates
Prospective Multi-Center Randomized Study for Evaluating the EVAHEART®2 Left Ventricular Assist System
NCT01187368
Recruiting
This is a prospective, multi-center, unblinded, randomized, controlled, and non-inferiority study comparing the EVA2 LVAS to the most recent magnetically levitated centrifugal LVAS (HM3 LVAS).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/20/2023
Locations: University of Virginia Medical Center, Charlottesville, Virginia
Conditions: Heart Failure
Register for Updates
Ortho-R® for Rotator Cuff Repair Compared With Standard of Care Rotator Cuff Repair Without Ortho-R®
NCT05333211
Recruiting
Phase I/II, multi-center, prospective, blinded 2arm, parallel design and randomized controlled study. Assessing the Ortho-R/PRP combination and standard of care for rotator cuff repair, will be compared though 12 months.
Gender:
All
Ages:
Between 40 years and 75 years
Trial Updated:
03/17/2023
Locations: OrthoVirginia, Richmond, Virginia
Conditions: Rotator Cuff Tears
Register for Updates